Pott G, Rauterberg J, Voss B, Gerlach U
Klin Wochenschr. 1982 Jan 4;60(1):1-7. doi: 10.1007/BF01721581.
In this second part, clinical aspects of connective tissue metabolism in the liver will be described and two main aspects considered. The first is the possibility to monitor the activity of fibrosis by the use of metabolites and enzymes of connective tissue metabolism. In recent studies the qualification for this purpose of enzymes such as procollagen prolyl hydroxylase and lysosomal N-Acetyl-beta-glucosaminidase and the N-terminal peptide of procollagen type III has been tested. The serum activities or concentrations of these substances in patients with chronic active liver diseases increase in due relation to the histologically estimated activity of liver fibrosis. The second aspect deals with therapeutic approaches to fibrosis in the liver by using connective tissue specific agents. So far none of the antifibrotic substances such as proline analogues, colchicine, lathyrogens and penicillamine has been used in longer-term antifibrotic treatment.
在第二部分中，将描述肝脏结缔组织代谢的临床方面，并考虑两个主要方面。第一个方面是利用结缔组织代谢的代谢物和酶来监测纤维化活动的可能性。在最近的研究中，已经测试了诸如前胶原脯氨酰羟化酶、溶酶体N-乙酰-β-氨基葡萄糖苷酶和III型前胶原N端肽等酶用于此目的的适用性。慢性活动性肝病患者血清中这些物质的活性或浓度与组织学评估的肝纤维化活性呈正相关。第二个方面涉及通过使用结缔组织特异性药物治疗肝脏纤维化的方法。到目前为止，诸如脯氨酸类似物、秋水仙碱、致纤维化剂和青霉胺等抗纤维化物质均未用于长期抗纤维化治疗。
